Biotech | April 09, 2026
Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
Germany will be the first launch market
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
Subscribe To Our Newsletter & Stay Updated
